MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202541124409 A) filed by Saveetha Institute Of Medical And Technical Sciences, Chennai, Tamil Nadu, on Dec. 10, 2025, for 'novel mri contrast agent formulation comprising of polyethyleneglycol coated iron oxide nano particles.'
Inventor(s) include Dr. Caroline Sylvia; Dr. P Vijayalakshmi; Dr. Paarthipan Natarajan; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses a novel magnetic resonance imaging (MRJ) contrast agent comprising polyethylene glycol (PEG)-coated iron oxide nanoparticles, specifically engineered for enhanced visualization of brain tumors. The iron oxide core imparts superparamagnetic properties, producing strong T2 relaxation effects and superior negative contrast in MRJ, while the PEG coating provides steric stabilization, biocompatibility, and resistance to aggregation. The PEGylation further prolongs systemic circulation, reduces clearance by the reticuloendothelial system, and enables effective accumulation in tumor tissue. The invention addresses critical limitations of conventional gadolinium-based agents, including nephrotoxicity, tissue deposition, and limited tumor specificity. By optimizing hydrodynamic size, surface functionalization, and colloidal stability, the PEG-coated nanoparticles demonstrate the ability to penetrate the blood-brain barrier and selectively localize within brain tumors through the enhanced permeability and retention effect. The resulting high relaxivity and tumor-specific accumulation provide sharper contrast, improved delineation of tumor margins, and greater diagnostic accuracy. In preferred embodiments, the nanoparticles exhibit minimal cytotoxicity, excellent in vivo biocompatibility, and stable dispersion in pharmaceutically acceptable earners suitable for intravenous administration. The invention therefore provides a next-generation MRI contrast formulation that integrates nanotechnology, surface chemistry, and biomedical imaging to deliver improved safety, enhanced sensitivity, and superior specificity for clinical neuro-oncological applications."
Disclaimer: Curated by HT Syndication.
